Neuroinflammation is a key feature of Alzheimer’s disease (AD). The activation of the NLRP3 inflammasome has been associated with the pathogenesis of AD, therefore, targeting NLRP3 may help reduce ...
NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time collaborator and advisor, Prof. Dr. Marc Donath ...
SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a biopharmaceutical company trading near its 52-week low of $1.67, has commenced Phase 2 trials for its NLRP3 inhibitor portfolio, targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback